Clinical causality assessment I. Ralph Edwards R.H.B Meyboom.

Slides:



Advertisements
Similar presentations
Pharmacology and the Nursing Process in LPN Practice
Advertisements

Andrea M. Landis, PhD, RN UW LEAH
The management of adverse drug reactions I Ralph Edwards
Safety Reporting IN Clinical Trials
Applying the Nursing Process to Drug Therapy
Causality Causality Hill’s Criteria Cross sectional studies.
Study Designs in Epidemiologic
EVIDENCE BASED MEDICINE for Beginners
Developing a Questionnaire. Goals Discuss asking the right questions in the right way as part of an epidemiologic study. Review the steps for creating.
Guidance for Industry Establishing Pregnancy Registries Pregnancy Registry Working Group Pregnancy Labeling Taskforce March, 2000 Evelyn M. Rodriguez M.D.,
Medical Reports Dr. Nasser Al - Jarallah.
Postmarketing Risk Assessment of Drug Products Division of Drug Risk Evaluation Office of Drug Safety Center for Drug Evaluation and Research.
IMPROVING THE DOCUMENTATION OF DIAGNOSES Carol A. Lewis.
Chapter 17 Nursing Diagnosis
How and Why Drugs Work Chapter 5
1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.
Chapter 5 Research Methods in the Study of Abnormal Behavior Ch 5.
SAE Report CTT21 V To:Quality Assurance Research & Development 34 Hyde Terrace LS2 9LN Date:…………………………….. Fax To:+44(0) From (name):………………………..
Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial Adverse Event Reporting Catherine Dillon.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
SERIOUS ADVERSE EVENTS REPORTING Elizabeth Dayag IRB Administrator Naval Medical Center Portsmouth.
1 Causation in Epidemiological Studies Dr. Birgit Greiner Senior Lecturer.
Why are we learning this? How scientific knowledge (pharmacology, therapeutics) and clinical skills (measuring blood pressure, glucoses, drug information)
Epidemiology The Basics Only… Adapted with permission from a class presentation developed by Dr. Charles Lynch – University of Iowa, Iowa City.
1 Nuts and Bolts of Safety Reporting The Role of the CRO Dr. Noa Lowenton Spier Pharma-Clinical S.A.G.
MCA Risk:benefit analysis of Kava-kava Update as at 12 Feb 2002.
Introduction to Pharmacology PHARM TECH. Pharmacology  Pharmacology is the science that deals with the study of therapeutic (beneficial) agents.  Knowledge.
PERIODIC MEDICAL EXAMINATION BY DR. ANGELA ESOIMEME MBBS, MPH, FWACGP.
CTD, Safety Tanja Braakman Genzyme Europe BV Pharmacovigilance Department.
Psychopathology Introduction. ource/view.php?id=6874http://vle.ccs.northants.sch.uk/mod/res ource/view.php?id=6874.
DRUGS OF ABUSE Reynaldo J. Lesaca, M.D. Reynaldo J. Lesaca, M.D.
Author Name: Kannika Inpra Presenter Name: Kannika Inpra Authors: Inpra K., Suwankesawong W., Kaewvichit S. Institution: Phrae.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 2 Application of Pharmacology in Nursing Practice.
DIVISION OF REPRODUCTIVE AND UROLOGIC PRODUCTS Physician Labeling Rule Lisa Soule, M.D.
Active Surveillance for Adverse Drug Events Dan Budnitz, MD, MPH National Center for Injury Prevention & Control November 9, 2004 Collaborative Effort.
EXPERIMENTAL EPIDEMIOLOGY
Causal relationships, bias, and research designs Professor Anthony DiGirolamo.
Quality Education for a Healthier Scotland Pharmacy Pharmaceutical Care Planning Vocational Training Scheme: Level = Stage 2 Arlene Shaw Specialist Clinical.
CAUSALITY ASSESSMENT OF SUSPECTED AEs Dr. Retesh Kumar Head, Global PhV Department 12/13/2015.
RELEVANCERELEVANCE Is the objective of the article on harm similar to your clinical dilemma? Yes, the article’s objective is similar to the clinical dilemma.
What pharmacovigilance can do for you! relationship assessment is a better concept 24 Nov Dar es Salaam.
Good Pharmacovigilance Practices
Inside Clinical Trials ® ALL RIGHTS RESERVED. What is a clinical trial? ALL RIGHTS RESERVED.
Sifting through the evidence Sarah Fradsham. Types of Evidence Primary Literature Observational studies Case Report Case Series Case Control Study Cohort.
Causality Assessment in postmarketing adverse events Anshu Vashishtha MD PhD Watson Pharmaceuticals.
Signal identification and development I.Ralph Edwards.
EVALUATING u After retrieving the literature, you have to evaluate or critically appraise the evidence for its validity and applicability to your patient.
Pharmacology and the Nursing Process in LPN Practice
Effets indesirables des médicaments Cours en partie basé sur source documentaire de l’OMS.
EBM --- Journal Reading Presenter :黃美琴 Date : 2005/10/27.
Department of Pharmacy, Ditmanson Medical Foundation Chia-Yi Christian Hospital Suspect Moxifloxacin Induced Torsades de Pointes: A case report Ya-Wen.
27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.
D3 ) Not Recovered d5) Fatal Was a post-mortem undertaken?YesNo Was the SAE ongoing at time of death from other cause? Yes No d d m m y y y y d1) Recovered.
Meet & Greet. Welcome Objectives: 1. Review the core terminology used in pharmacology. 2. Discuss the features of the “perfect” drug. 3. Examine the.
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
Detection & monitoring of ADR
1st International Online BioMedical Conference (IOBMC 2015)
8. Causality assessment:
Safety Reporting Nichol McBee, MPH, CCRP.
Prescribing.
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
Pharmacovigilance in clinical trials
*Continue on SAE supplemental page CTT21 A if more space is required
9. Introduction to signal detection
The Nursing Process and Pharmacology Jeanelle F. Jimenez RN, BSN, CCRN
SERIOUS ADVERSE EVENTS REPORTING
Module 6 Rotavirus vaccine AEFI monitoring
Causality assessment Using causality models
Pharmaceutical care plans Ola Ali Nassr
Presentation transcript:

Clinical causality assessment I. Ralph Edwards R.H.B Meyboom

Causality assessment Perspectives patient treating doctor drug manufacturer drug control authority

Causality assessment Three Key Questions Can the drug cause the adverse reaction? Has the drug caused the adverse reaction? Will the drug cause the adverse reaction?

Causality assessment how likely is it that this medication is the cause of this problem in this particular patient? making a differential diagnosis

Categories of disease aetiology Sufficient causes. On exposure to a sufficient cause, the disease will inevitably follow. (Type A effects.) Necessary causes. Although exclusion of a necessary cause inevitably prevents the disease, exposure is not invariably followed by development of the disease. (Type B effects.) Contributory causes. Increase the risk of a given disease. Exclusion leads to reduction in frequency but not eradication of the disease. (Type C effects.)

Approaches to causality assessment individual expert panel of experts formal algorithm –decrease inter-individual differences –improve validity? –time consuming

Causality assessment First step Make sure you have access to all available details

Data elements relevant to causality assessment Age, sex and medical history Identified suspected and other drugs, doses, routes, start stop dates and indications for use Description of adverse event, including clinical data, laboratory results and date of onset (or interval) Treatment, course and outcome

Four assessment criteria The association in time (place) between drug administration and event Pharmacology (features, previous knowledge of side effects) Medical plausibility (characteristic signs and symptoms, laboratory tests, patho- logical findings) Likelihood or exclusion of other causes

Causality assessment Reasonable time relationship –pharmacokinetics –type of reaction Site of reaction Dose-response –effect of dose reduction –effect of re-exposure Known actions of the drug Other drugs taken –traditional remedies Effects of underlying disease or conditions Main factors to consider

Causality assessment Are there previous conclusive reports on this reaction? Did the ADR appear after the suspected drug was administered? Did the ADR improve when the drug was discontinued or a specific antagonist was administered? Did the ADR reappear when the drug was readministered? Was the ADR confirmed by objective evidence

Causality assessment Are there alternative causes that could on their own have caused the reaction? Did the ADR reappear when a placebo was given? Was the drug detected in the blood (or other fluids) in concentrations known to be toxic? Was the ADR more severe when the dose was increased or less severe when the dose was decreased? Did the patient have a similar ADR to the same or similar drugs in any previous exposure?

WHO Causality Categories Certain Event or laboratory test abnormality, with plausible time relationship to drug intake, cannot be explained by disease or other drugs Response to withdrawal plausible (pharmaco-logically, pathologically) Event definitive pharmacologically or phenomenologically (An objective and specific medical disorder or a recognised pharmacological phenomenon) Rechallenge (if necessary)

WHO Causality Categories Probable Event or laboratory test abnormality, with reasonable time relationship to drug intake, unlikely to be attributed to disease or other drugs Response to withdrawal clinically reasonable Rechallenge not necessary

WHO Causality Categories Possible Event or laboratory test abnormality, with reasonable time relationship to drug intake, could also be explained by disease or other drugs Information on drug withdrawal lacking or unclear

WHO Causality Categories Unlikely Event or laboratory test abnormality, with a time to drug that makes a relationship improbable (but not impossible) Diseases or other drugs provide plausible explanations

WHO Causality Categories Conditional/Unclassified Event or laboratory test abnormality More data for proper assessment needed or additional data under examination

WHO Causality Categories Unassessable/Unclassifiable A report suggesting an adverse reaction Cannot be judged because of insufficient or contradictory information Report cannot be supplemented or verified

Major uses of causality assessment Signal detection Drug regulation Scientific publications Data exchange

What causality assessment can do Decrease disagreement between assessors Classify relationship likelihood (semi- quantitative) Mark individual case reports Education / improvement of scientific assessment

What causality assessment cannot do Give accurate quantitative measurement of relationship likelihood Distinguish valid from invalid cases Prove the connection between drug and event Quantify the contribution of a drug to the development of an adverse event Change uncertainty into certainty

Questions for the future Causality assessment as a routine of all reports, or only in selected cases? One general system, or special systems adapted to specific adverse reactions?